Observational studyHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2026
Effects of Non-statin Lipid-Lowering Therapies Implementation and Statin Treatment Intensification on Lipid Status in Heart Transplant Recipients: A Single-Centre Retrospective Cohort Study.
Observational study in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStatin therapy up-titration is hindered in heart-transplant (HT) recipients due to concern for pharmacological interactions and side effects. Alternative lipid lowering therapies (LLT) are now available for patients who are poorly tolerant to statins or those with significant dyslipidaemia despite maximal dose statin treatment and dietary advice. Real-world studies with non-statin LLT are limited in HT population.
aimTo examine the lipid status of HT patients following the increased adoption of non-statin lipid lowering therapies.
methodsSingle centre retrospective observational cohort study including adult HT patients under follow-up in a tertiary centre. From August 2024 to March 2025, 238 patients had lipid profile, prevalence of statin and non-statin LLT prescription assessed and compared to the same data measured in 2019/2020.
resultsPatients had a median age of 64 (IQR=53.3-72.0) years, 27% were female. Median LDL-C levels for paired values significantly decreased from 109.6 [88.9-133.0] to 93.8 [72.5-112.0] at last follow up (p<0.001). The proportion of patients receiving ezetimibe sharply increased [73 (30.7%) compared to 27 (11.3%), p<0.001]; 10 patients (4.2%) were receiving proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibodies (PCSK9i), 3 (1.3%) inclisiran, 3 (1.3%) bempedoic acid, which were not commercially available at the time of the previous assessment. Also, the proportion of patients receiving statins increased during follow-up [145 (60.9%) vs 128 (52.1%), p<0.001], mainly because of high-intensity statin adoption.
conclusionIn a real-world cohort of HT recipients, increased adoption of ezetimibe, PCSK9-targeting therapies and bempedoic acid combined with intensification of statin therapy safely and efficiently reduced LDL-C.
Indexed as
Identifiers
42084826What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.